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cidence of acute toxic effects of the conditioning regimen (Maris et
al 2001) but require a greater patient and family participation in the
direct care. Many transplant centers plan to have all or part of the
care provided in the outpatient setting and need the support of
families and friends as caregivers. Much of the printed education
materials available to transplant patients is directed to ablative
transplants and can be misleading to patients and families. The
Allogeneic Patient Handbook at Duke Adult Stem Cell Transplant
(ASCT) Program contains patient instructions for high dose abla-
tive transplants.
Duke University Medical Center performed 36 non-myeloabla-
tive transplants in ﬁscal year 2003. Only 22% of these patients were
admitted to the hospital. The majority of the patients received all
of their care in the Adult Outpatient Clinic and at home with
assistance from home care services and family caregivers. A new set
of teaching guidelines, materials and methods need to be developed
in order to meet the changing education needs of transplant pa-
tients.
Prior to developing new materials and processes, the non-my-
eloablative transplant patients were surveyed by the ASCT pro-
gram nursing staff to determine how the current handbooks met
the educational needs and what opportunities did we have to
improve the content and the process. Patient satisfaction surveys
were also used to determine patient satisfaction with the educa-
tional process.
The Non-myeloablative Patient Handbook was written and re-
viewed by the Adult BMT Clinical Staff and approved by the Duke
Oncology Patient Education Committee.
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IMPLEMENTING BROVIAC CATHETER USE IN PHOTOPHERESIS FOR
CHRONIC GVHD IN PEDIATRIC HSCT PATIENTS
Fisher, V.L., Jekutis, B., Smucker, T. Rainbow Babies and Children’s
Hospital/Ireland Cancer Center, Cleveland, OH
The use of photophersis in the treatment of chronic GVHD has
been well documented in the adult HSCT patient population.
However, the use of photophersis in the pediatric HSCT patient
remains a formidable challenge, due to central access issues. May
institutions require pheresis catheter placement for photopheresis.
We report a series of 142 successful photopheresis sessions in ﬁve
pediatric patients utilizing a double lumen broviac catheter. All of
the patients had malignacies (2 ALL and 3 AML) The patients
ranged in age from 8-15 years and with weights of 20.1 kg to 58 kg
respectively. The number of photopheresis sessions for the patients
ranged from 8 to 52. The ECP procedure was performed using the
UVAR XTS photopheresis system (Therakos, West Chester, Pa)
as previously described. The mean treatment time for each pho-
topheresis procedure was 3.5 hours. The ﬂow rate during each
photophersis procedure averaged 10-12 ml/minute. Only one of
the ﬁve patients experienced hypovolemia as an adverse event,
successfully treated with ﬂuid replacement. There were no other
adverse events related to photopheresis. The use of tPA was re-
quired occasionally prior to the start of the procedure. We con-
clude that the use of a broviac catheter is a safe and practical
alternative to apheresis catheters for management of chronic
GVHD in pediatric HSCT patients.
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HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM DISTRESS IN
PATIENTS PRIOR TO ALLOGENEIC STEM CELL TRANSPLANT
Bevans, M.1, Marden, S.1, Mayberry, H.1, Cusack, G.1, Soeken, K.2,
Kline Leidy, N.3 1. National Institutes of Health, Clinical Center,
Nursing and Patient Care Services, Bethesda, MD; 2. University of
Maryland, Baltimore, MD; 3. MEDTAP International, Bethesda, MD
Objective: This study examined health-related quality of life
(HRQL) and symptom distress (SD) in patients preparing to un-
dergo allogeneic stem-cell transplant (A-SCT) for the treatment of
hematological diseases. Methods: Prospective survey of patients
enrolled in an A-SCT clinical trial. HRQL was measured by the
physical (PCS) and mental (MCS) health scores of the Short
Form-36 (norm  50) and the Functional Assessment of Cancer
Therapy-General (FACT-G; range 0-100). SD was measured by
the Symptom Distress Scale (SDS; range 13-65). Patients com-
pleted the questionnaires in English or Spanish via a touch-screen
computer during the trial baseline period. Scores were compared
to published references for the 1998 general United States (US)
population (GP) and a cancer population (CP) using one sample
t-tests. Scores were also grouped by gender and compared to the
male/female GP using one sample t-tests. A p-value 0.05 was
considered signiﬁcant. Findings: Patients (N  76) were mostly
male (67%), ranging in age from 18-71 years (M  40; SD  14),
and either Caucasian (46%) or Hispanic (30%). Most (97%) had
ECOG 1. Baseline results demonstrated mean PCS and MCS
scores of pre-A-SCT patients were signiﬁcantly lower than the GP
(norm 50 vs. 43, p 0.001 and 47, p 0.015, respectively). The
mean PCS score for male patients was signiﬁcantly lower than male
GP (norm  51 vs. 42; p  0.001); mean MCS score did not differ
(norm  51 vs. 49; p  0.20). For female patients, the mean MCS
score was signiﬁcantly lower than female GP (norm  50 vs. 43;
p  .017); mean PCS score did not differ (norm 49 vs. 44; p 
0.05). FACT-G total score was signiﬁcantly lower than patients
with Hodgkin’s Disease (59 vs. 66; p  0.001). SDS scores (76%)
indicated low SD (25); 24% indicated moderate distress (range
25-32). Conclusion: Patients with hematological diseases, ECOG
1, prior to A-SCT have poorer HRQL compared to the US GP
and a cancer population, with relatively low levels of SD. Men
report more concerns related to physical health compared to men
in the GP. Women report more concerns related to mental health
compared to women in the GP.
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CONTINUOUS PLATELET DRIP: A UNIQUE APPROACH IN THE TREAT-
MENT OF SEVERE/REFRACTORY THROMBOCYTOPENIA IN THE PEDI-
ATRIC STEM CELL TRANSPLANT POPULATION
Talbert, G.1,2, Zbylut, C.1, Chelf, K.1, Frey, M.A.1,2, Martin, P.2,
Kurtzberg, J.2 1. The Duke University Children’s Hospital, Durham,
NC; 2. The Pediatric Stem Cell Transplant Program at Duke Univer-
sity, Durham, NC
Thrombocytopenia is an expected complication of marrow abla-
tive therapy. Platelets are the last hematopoietic cell to ablate and
the last to recover after conditioning for tranplant. Bleeding re-
mains a signiﬁcant cause of morbidity and morality in the im-
munosuppressed patients. Patients undergoing stem cell transplan-
tation are at greater risk due to the prolonged duration and severe
nature of the aplastic period. Therefore, long term supportive care
via platelet transfusion is a common and expected therapy in this
patient population. As a result of therapy, many patients become
refractory to platelet transfusions. These patients may require
more intensive measures that include frequent platelet transfusions
or continuous platelet drips to prevent complications from bleed-
ing. To further complicate matters, many patients undergoing
transplantation are often ﬂuid sensitive and at times ﬂuid re-
stricted. The added volume of multiple platelet transfusions can
pose additional risk to an already fragile patient. The use of
continuous platelet drips has proven to be an effective way to treat
severe/refractory thrombocytopenia and minimize the additional
ﬂuid volume. The Duke Pediatric Stem Cell Transplant Unit
utilizes continuous platelet drips for select patients. Patients re-
ceiving this therapy must meet speciﬁc criteria including throm-
Table. Patient Demographics
Age Sex Diagnosis HSCT Source GVHD
10 F ALL CR3 MUD-PB (6/6) Extensive
13 M ALL CR2 MUD-BM (6/6) Extensive
15 F AML CR2 MRD-PB (5/6) Extensive
15 M AML CR1 MRD-BM (5/6) Extensive
8 M AML CR3 UCB (4/6) Extensive
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bocytopenia that is refractory despite twice-daily platelet tranfu-
sions and a high risk for bleeding. The purpose of this abstract is
to describe the indications, risks, beneﬁts, and nursing challenges
associated with continuous platelet drips.
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THE DUKE PEDIATRIC STEM CELL TRANSPLANT SAFETY PROGRAM: AN
INITIATIVE TO REDUCE RISK AND IMPROVE PATIENT OUTCOMES
Frey, M.A.1,2, Talbert, G.1,2 1. The Duke University Children’s Hos-
pital, Durham, NC; 2. The Duke Pediatric Stem Cell Program,
Durham, NC
The development of innovative and progressive treatment op-
tions can greatly increase the risks to patients. Complex treatment
plans become more difﬁcult to administer in light of a regional and
national nursing shortage. Many transplant programs struggle with
recruiting and retaining top talent. Nowhere are safety concerns
more apparent than in the treatment of pediatric bone marrow and
stem cell transplant patients. The Duke Pediatric Transplant Pro-
gram typically treats high risk patients. The 16 bed inpatient unit
runs an occupancy rate of over 90%. The nurses on this unit
provide many high risk (and sometimes low volume) procedures
that require specialized training and a heightened awareness of
safety precautions. The unit administers more than 18,000 medi-
cations and 500 blood products per month. Nurses on Duke’s
Pediatric Stem Cell Transplant unit administer high dose chemo-
therapy, blood products, antibiotics, anti-GVHD medications,
parenteral nutrition and other supportive drugs. Additionally, the
program provides intensive care measures that require a specialized
care delivery model. The purpose of this poster will be to outline
the inherent risks associated with pediatric stem cell transplanta-
tion. In 2003 The Duke Children’s Hospital began a Patient Safety
Initiative. The goals of the program are to identify high risk
procedures and therapies and to develop and implement a plan to
minimize or eliminate the risk to the patient. The major goal of
this poster will be to describe the safety measures implemented for
this high risk population. Included in the discussion are safety
checks, staff training and competencies, and equipment safety. All
safety initiatives are monitored on a monthly basis and reviewed by
leadership at all levels within the organization. This information is
also presented to staff at the unit level for feedback and recom-
mendations for change if needed.
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CO-MORBIDITIES AGING POPULATION ON THE RISE
Rivera, Z.R. University of Texas MD Anderson Cancer Center, Hous-
ton, TX
Bone Marrow Transplantation (BMT) is a specialty area in On-
cology that is challenging in many aspects for nurses. In addition to
post transplant issues is the nursing management of BMT patients
with co-morbidities. Nursing implications are tremendous in car-
ing for patients who are older, acutely ill, or have functional
limitations.
According to Healthy People 2010 the initiatives set are to
increase quality of life and decrease health disparities. Predictably,
the aging population will result in increased incidence of chronic
diseases including cardiac issues and cancer. Offering BMT to
older patients is increasing because of the advent of less toxic
regimens, we are not just dealing with one chronic condition. By
2010 estimations state there will be 40 million Americans age 65 or
older. The average rates of cardiovascular events rise from 7 per
1,000 men ages 35-44 to 68 per 1,000 men ages 85-94 with
narrowing gaps with advancing age and comparable rates occur 10
years later in life for women (NHLBI Framingham Heart Study).
An increased incidence of end-stage renal disease has been noted in
the elderly aged 70-74. As is evident by some of these statistics,
Americans are sicker compounded with more ailments resulting in
hospitalizations and prolonged medical treatments.
Age related chronic diseases have potential to impact the treat-
ment course for BMT recipients. Research shows that common
co-morbidities are cardiovascular, respiratory, renal, or endocrine
related. Shahjahan et al. has documented retrospective data at our
center studying effects of co-morbidity in AML/MDS patients.
Critical management of these patients with their age related
conditions is essential in preserving quality of life. It is important
to know contributing factors in patients’ history and to maintain
current knowledge related to the management of these co-morbid
conditions. Responsibility lies among all members of the team,
especially the nurse giving direct patient care.
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